PBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS
PBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS
Recruiting · NCT07761533 · Registry updated 2026-08-14Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| PBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, anemia, bone marrow disorder, hematologic disorder, leukemia, myelodysplastic syndrome, myelodysplastic syndrome with excess blasts, myelodysplastic syndrome with single lineage dysplasia, myeloid leukemia, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-08-14 | NCT07761533 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Chaser Therapeutics, Inc. | 1 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| The First Affiliated Hospital of Zhejiang University school of medicine | Hangzhou | China | 18 |